Results 1 to 10 of about 698 (85)

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease [PDF]

Antimicrobial Agents and Chemotherapy
The guideline-based therapy achieves sputum culture conversion rates in 20%–34% of patients with Mycobacterium abscessus (MAB) lung disease (LD). Double-β-lactam combinations have been proposed to improve cure based on time-kill curves.
Sanjay Singh, Avneesh Shrivastava, Gunavanthi D. Boorgula, Mary C. Long, Brian Robbins, Pamela J. McShane, Tawanda Gumbo, Shashikant Srivastava   +7 more
doaj   +2 more sources

Consistent in vitro activity of sulbactam-durlobactam against genetically diverse carbapenem-resistant Acinetobacter baumannii in a high-endemic Brazilian setting [PDF]

Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes high-mortality infections, with limited treatment options. We evaluated sulbactam-durlobactam activity against 94 isolates from Brazil.
Gabriela da Silva Collar, Luana Silva Dornelles, Júlia Cover Salvador, Jaqueline Becker Pinto, Dariane Castro Pereira, Patrícia Orlandi Barth, João Vitor Barboza Cardoso, William Latosinski Matos, Mariana Preussler Mott, Afonso Luís Barth, Andreza Francisco Martins, Juliana Caierão   +11 more
doaj   +2 more sources

Sulbactam–durlobactam and cefiderocol combination treatment of Burkholderia cenocepacia-associated Fitz–Hugh–Curtis syndrome [PDF]

Antimicrobial Agents and Chemotherapy
A 50-year-old woman with cystic fibrosis (CF) and lung transplantation developed persistent deep abscesses due to multidrug-resistant (MDR) Burkholderia cenocepacia, unresponsive to multiple antibiotics and surgeries.
Bhavita Gaglani, Tessa M. Andermann, Claire Wate, Jorge Oldan, Chirag S. Desai, Steven H. Marshall, Robert A. Bonomo, Ray Coakley, David van Duin, Anne Lachiewicz   +9 more
doaj   +2 more sources

Sulbactam–Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii: A Narrative Review [PDF]

Antibiotics
The increasing prevalence of infections caused by multidrug-resistant (MDR) Gram-negative bacteria represents a major global public health challenge.
Szymon Viscardi, Patrycja Lipska, Piotr Niezgódka, Anna Duda-Madej   +3 more
doaj   +2 more sources

Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex [PDF]

Pathogens
Carbapenem-resistant Acinetobacter baumannii infections pose a significant challenge due to their severity and the poor prognoses they often result in, particularly in cases where there are risk factors present. The United States (US) Centers for Disease
Francesco Nappi
doaj   +2 more sources

Salvage Treatment of Ventilator-Associated Pneumonia Using Sulbactam–Durlobactam in a Preterm Neonate: A Case Report [PDF]

Infectious Disease Reports
Background: Ventilator-associated pneumonia (VAP) is a leading cause of nosocomial infections in neonatal intensive care units (NICUs) and is associated with significant morbidity, mortality, and prolonged hospitalization, particularly in preterm ...
Suzana Zivojinovic, Tijana Prodanovic, Nikola Prodanovic, Rasa Medovic, Milica Cekerevac, Dragana Savic, Bojana Markovic, Slobodan Jankovic   +7 more
doaj   +2 more sources

Low-dose sulbactam-durlobactam for recurrent CRAB pneumonia in a child with cerebral palsy: a Case Report from a resource-limited setting [PDF]

Frontiers in Pharmacology
BackgroundPediatric data for sulbactam-durlobactam (SUL-DUR) are extremely scarce, and no standard pediatric dosing exists.MethodsWe report a 6-year-old boy with cerebral palsy and epilepsy who developed recurrent ventilator-associated pneumonia caused ...
Mengting Li, Mengting Li, Haotian Fei, Haotian Fei, Liang Huang, Liang Huang, Lu Qing, Lu Qing, Xiaoliang Liu, Xiaoliang Liu, Guoyan Lu, Guoyan Lu   +11 more
doaj   +2 more sources

In Vitro Antibacterial Activity of Sulbactam-Durlobactam and Eravacycline Against Carbapenem-Resistant Acinetobacter baumannii in China and Analysis of Sulbactam-Durlobactam Resistance Mechanisms [PDF]

Polish Journal of Microbiology
The management of carbapenem-resistant Acinetobacter baumannii (CRAB) infections remains a formidable clinical challenge. This study evaluated the in vitro antimicrobial activities of sulbactam-durlobactam (SUL-DUR) and eravacycline (ERV) against CRAB ...
He Xuelian, Ma Shang, Zhou Yanyan, Wei Jingjuan, Zhuo Zhongling, Ma Liyan   +5 more
doaj   +2 more sources

Resistance of Acinetobacter baumannii Complex Clinical Isolates to Sulbactam–Durlobactam: A Systematic Review of Data from In Vitro Studies [PDF]

Pathogens
Introduction: Due to the limited therapeutic options for patients with Acinetobacter baumannii complex infections, a new combination antimicrobial agent, sulbactam–durlobactam, has been developed.
Matthew E. Falagas, Laura T. Romanos, Dimitrios Ragias, Charalampos Filippou   +3 more
doaj   +2 more sources

Antimicrobial activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex strains causing non-respiratory and non-bloodstream infections from the United States (2023–2025) [PDF]

Microbiology Spectrum
Acinetobacter baumannii most often causes pneumonia in critically ill patients. However, A. baumannii is also an important cause of a broader range of infections, including skin/wound and urinary tract infections. This study aims to evaluate the in vitro
Elizabeth Cyr, Jill Argotsinger, Eric T. Beck, Robin R. Chamberland, Andrew E. Clark, Anne R. Daniels, Rachael Liesman, Mark Fisher, Philip Gialanella, Jonathan Hand, Amanda T. Harrington, Romney M. Humphries, Holly Huse, Robert Hamilton-Seth, Julia D. Hankins, Wesley D. Kufel, Scott W. Riddell, Meera Mehta, Ryan Demkowicz, A. Brian Mochon, Hossein Salimnia, Ayesha Khan, Virginia M. Pierce, Raghava Potula, Tsigereda Tekle, Patricia J. Simner, Robert J. Tibbetts, Christine Vu, Lilian M. Abbo, Octavio Martinez, Rebekah E. Dumm, Manohar B. Mutnal, Timothy C. Jenkins, Violeta Chávez, Paulette Pinargote, Jennifer Bowling, Erik Munson, Daniel V. Zurawski, David P. Nicolau, Tomefa E. Asempa   +39 more
doaj   +2 more sources